LLY

890.27

+1.4%↑

JNJ

241.35

+0.45%↑

ABBV

211.76

+0.99%↑

NVS

149.7

+0.98%↑

MRK

121.04

+1.14%↑

LLY

890.27

+1.4%↑

JNJ

241.35

+0.45%↑

ABBV

211.76

+0.99%↑

NVS

149.7

+0.98%↑

MRK

121.04

+1.14%↑

LLY

890.27

+1.4%↑

JNJ

241.35

+0.45%↑

ABBV

211.76

+0.99%↑

NVS

149.7

+0.98%↑

MRK

121.04

+1.14%↑

LLY

890.27

+1.4%↑

JNJ

241.35

+0.45%↑

ABBV

211.76

+0.99%↑

NVS

149.7

+0.98%↑

MRK

121.04

+1.14%↑

LLY

890.27

+1.4%↑

JNJ

241.35

+0.45%↑

ABBV

211.76

+0.99%↑

NVS

149.7

+0.98%↑

MRK

121.04

+1.14%↑

Home・Akciju saraksts・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Atvērts

SektorsVeselības aprūpe

26.49 0.15

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

26.29

Max

26.52

Galvenie mērījumi
By Trading Economics
Ienākumi	-28M 22M
Pārdošana	4.3M 244M
P/E Sektora vidējais	10.185 57.05
EPS	1.08
Peļņas marža	9.224
Darbinieki	293
EBITDA	-22M 52M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+55.43% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	49M 1.6B
Iepriekšējā atvēršanas cena	26.34
Iepriekšējā slēgšanas cena	26.49

Ziņu noskaņojums

By Acuity

40%

60%

120 / 349 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bullish Evidence

29.8 / N/A Atbalsts un pretestība

Harmony Biosciences Holdings Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 27. marts 17:33 UTC

Galvenie ziņu notikumi

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

2026. g. 27. marts 17:00 UTC

Galvenie ziņu notikumi

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

2026. g. 27. marts 16:03 UTC

Galvenie ziņu notikumi

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

2026. g. 29. marts 23:47 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Falls Amid Rising Inflation Fears -- Market Talk

2026. g. 29. marts 23:46 UTC

Tirgus saruna

Galvenie ziņu notikumi

Nikkei May Fall on Fears About Shortage of Petrochemical Products -- Market Talk

2026. g. 29. marts 23:35 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Rises on Supply-Disruption Concerns Spurred by Widening Mideast Conflict -- Market Talk

2026. g. 29. marts 23:23 UTC

Tirgus saruna

Australia's National Cabinet to Avoid Covid-Style Measures -- Market Talk

2026. g. 29. marts 22:34 UTC

Tirgus saruna

Macroeconomic Tailwind for Warehouse Dissipates -- Market Talk

2026. g. 29. marts 22:09 UTC

Tirgus saruna

Amplitude's Next Well "Effectively a Must-Win" for Growth Thesis -- Market Talk

2026. g. 29. marts 21:06 UTC

Tirgus saruna

Galvenie ziņu notikumi

Australia's Economy Could Already Be Contracting Amid Oil Shock -- Market Talk

2026. g. 29. marts 21:03 UTC

Tirgus saruna

Australia's Government Wants to Avoid Heavy Handed Oil Shock Response -- Market Talk

2026. g. 29. marts 21:01 UTC

Tirgus saruna

Galvenie ziņu notikumi

Australian National Cabinet Meeting to Focus on Oil Supply -- Market Talk

2026. g. 29. marts 09:30 UTC

Iegādes, apvienošanās, pārņemšana

Food Mega-Mergers Hardly Ever Work. Could McCormick-Unilever Be Different? -- Heard on the Street -- WSJ

2026. g. 28. marts 08:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 27. marts 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 27. marts 19:16 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

2026. g. 27. marts 19:07 UTC

Tirgus saruna

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

2026. g. 27. marts 19:04 UTC

Tirgus saruna

Gold Rises But Can't Finish the Week Positive -- Market Talk

2026. g. 27. marts 19:03 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 27. marts 19:02 UTC

Tirgus saruna

Galvenie ziņu notikumi

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

2026. g. 27. marts 18:12 UTC

Tirgus saruna

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

2026. g. 27. marts 17:36 UTC

Galvenie ziņu notikumi

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

2026. g. 27. marts 17:34 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

2026. g. 27. marts 17:29 UTC

Tirgus saruna

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

2026. g. 27. marts 16:38 UTC

Tirgus saruna

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

2026. g. 27. marts 16:32 UTC

Tirgus saruna

Galvenie ziņu notikumi

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

2026. g. 27. marts 16:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 27. marts 15:43 UTC

Tirgus saruna

Galvenie ziņu notikumi

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

2026. g. 27. marts 15:25 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 27. marts 15:25 UTC

Tirgus saruna

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

Salīdzinājums

Cenas izmaiņa

Harmony Biosciences Holdings Inc Prognoze

Cenas mērķis

By TipRanks

55.43% augšup

Prognoze 12 mēnešiem

Vidējais 41.25 USD 55.43%

Augstākais 62 USD

Zemākais 25 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Harmony Biosciences Holdings Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Harmony Biosciences Holdings Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

29.8 / N/AAtbalsts un pretestība

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Noskaņojums

By Acuity

120 / 349 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.